Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Leukemia, Myeloid, Acute 104Multiple Myeloma 66Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Myelodysplastic Syndromes 51Lymphoma, Non-Hodgkin 51Leukemia 50Hodgkin Disease 42Lymphoma, Mantle-Cell 29Lymphoma, Large B-Cell, Diffuse 29Leukemia, Lymphocytic, Chronic, B-Cell 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23Lymphoma, Follicular 22Burkitt Lymphoma 22Breast Neoplasms 22Recurrence 20Neoplasms, Plasma Cell 18Neuroblastoma 17Hematologic Neoplasms 17Lymphoma, B-Cell, Marginal Zone 15Myeloproliferative Disorders 14Lymphoma, Large-Cell, Immunoblastic 14Leukemia, Myelomonocytic, Chronic 12Leukemia, Biphenotypic, Acute 12Congenital Abnormalities 12Blast Crisis 10Anemia, Refractory, with Excess of Blasts 10Retinoblastoma 9Central Nervous System Neoplasms 9Sarcoma 8

Interventions

Cyclophosphamide 65Rituximab 62fludarabine 40Etoposide 25Lenalidomide 19fludarabine phosphate 17Immunotherapy, Adoptive 17Doxorubicin 17Cytarabine 17Vincristine 15Magnetic Resonance Spectroscopy 14Prednisone 13pembrolizumab 11Specimen Handling 11Dexamethasone 10CT-P10 10Melphalan 9Carmustine 9Carboplatin 9Bortezomib 9Bendamustine Hydrochloride 9obinutuzumab 8ibrutinib 8Mycophenolic Acid 8Biopsy 8Radiotherapy 7Ifosfamide 7polatuzumab vedotin 6Whole-Body Irradiation 6Methotrexate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell × Granulocyte Colony-Stimulating Factor × Clear all
NCT03579927 2020-01-29

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

NCT00379574 2013-03-15

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Asan Medical Center

Phase 1/2 Completed
49 enrolled 8 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡